Abstract 197P
Background
This study aimed to investigate characteristics, treatment patterns and clinical outcomes of Chinese patients with UAM GA/GEJA in real-world settings.
Methods
This was a multicenter, retrospective, observational study using electronic medical records from four tertiary hospitals. Adult patients who were diagnosed with UAM GA/GEJA between Jan 1, 2017 and Dec 31, 2020 and had ≥1 inpatient admission related to UAM GA/GEJA from diagnosis to Aug 31, 2021 were included. Descriptive statistics were applied to summarize the data and Kaplan- Meier method was used to describe duration of treatment (DoT) and progression-free survival (PFS) by each line of therapy.
Results
Of the 2,745 eligible patients (median age 62 years, 69.2% male), 97.3% had a diagnosis of GA, 94.0% had stage IV disease, and 43.4% had peritoneum metastasis at diagnosis. Of the 2,745 patients, 1,902 (69.3%) received first-line (1L) therapy. Of the 1,902 patients, 729 (38.3%) subsequently received second-line (2L) therapy and 284 (14.9%) received third-line (3L) therapy. The majority of patients received chemotherapy alone in 1L and 2L settings (84.1% in 1L, 63.6% in 2L, 41.4% in 3L). Targeted therapy-based regimen (13.7% in 1L, 30.3% in 2L, 49.2% in 3L) and immunotherapy-based regimen (3.1% in 1L, 8.7% in 2L, 18.5% in 3L) were used more often in 3L setting. The most frequently used treatment regimen in 1L, 2L, and 3L were fluoropyrimidine (FP) plus platinum (44.5%), FP plus taxanes (16.5%), and anti-angiogenic tyrosine kinase inhibitors alone (18.2%), respectively. Median (95% CI) DoT (4.4 months [4.2, 4.8] in 1L, 3.1 months [2.7, 3.6] in 2L, 2.4 months [2.0, 2.9] in 3L) and PFS (6.5 months [6.1, 6.9] in 1L, 4.2 months [3.7, 4.5] in 2L, 3.2 months [2.8, 3.7] in 3L) decreased progressively with each advancing line of therapy.
Conclusions
Patients treated in 1L and 2L mainly received chemotherapy alone at that time. DoT and PFS were generally short in all lines of therapy, which suggests the need for more effective new treatment options.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Eli Lilly and Company.
Funding
Eli Lilly and Company.
Disclosure
G. Segall, L. Zhou, C. Zhou, M. Khanal: Financial Interests, Personal, Full or part-time Employment: Eli Lilly and Company; Financial Interests, Personal, Stocks/Shares: Eli Lilly and Company. All other authors have declared no conflicts of interest.
Resources from the same session
5P - Clinicopathologic features and genomic profiling of occult breast cancer
Presenter: Liansha Tang
Session: Poster Display
Resources:
Abstract
6P - Tumor cell-released autophagosomes (TRAPs) promote lung metastasis through inducing PD-L1 high expression of pulmonary vascular endothelial cells (PVECs) in breast cancer
Presenter: Xuru Wang
Session: Poster Display
Resources:
Abstract
7P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: Xiaohe Zhou
Session: Poster Display
Resources:
Abstract
9P - Clinicopathological features and prognosis of mucinous breast cancer: A retrospective analysis of 358 patients in Vietnam
Presenter: Hoai Hoang
Session: Poster Display
Resources:
Abstract
10P - Comparison of 28-gene and 70-gene panel in risk-prediction of Chinese women with early-stage HR-positive and HER2-negative breast cancer
Presenter: Lei Lei
Session: Poster Display
Resources:
Abstract
11P - Multimodal analysis of methylation and fragmentomic profiles in plasma cell-free DNA for differentiation of benign and malignant breast tumors
Presenter: Hanh Nguyen
Session: Poster Display
Resources:
Abstract
12P - Plasma cell-free mRNA profiles enable early detection of breast cancer
Presenter: Chi Nguyen
Session: Poster Display
Resources:
Abstract
13P - Relationship of distress and quality of life with gut microbiome composition in newly diagnosed breast cancer patients: A prospective, observational study
Presenter: Chi-Chan Lee
Session: Poster Display
Resources:
Abstract
14P - Classification of molecular subtypes of breast cancer in whole-slide histopathological images using a novel deep learning algorithm
Presenter: Hyung Suk Kim
Session: Poster Display
Resources:
Abstract
15P - The regulation of pregnenolone in breast cancer
Presenter: Hyeon-Gu Kang
Session: Poster Display
Resources:
Abstract